Bone Mineral Density Response to Long-Term Bisphosphonate Therapy in Fibrous Dysplasia

Weinstein, 1991, Activating mutations of the stimulatory G protein in the McCune Albright syndrome, N Engl J Med, 325, 1688, 10.1056/NEJM199112123252403 Candeliére, 1997, Polymerase chain reaction-based technique for the selective enrichment and analysis of mosaic arg201 mutation in G∝s from patients with fibrous dysplasia, Bone, 21, 201, 10.1016/S8756-3282(97)00107-5 Liens, 1994, Long-term effects of intravenous pamidronate in fibrous dysplasia of bone, Lancet, 343, 953, 10.1016/S0140-6736(94)90069-8 Chapurlat, 1997, Long-term effects of intravenous pamidronate in fibrous dysplasia of bone, J Bone Miner Res, 12, 1746, 10.1359/jbmr.1997.12.10.1746 Chapurlat, 1998, Extended follow-up of patients with fibrous dysplasia of bone treated with pamidronate, Bone, 22, 56S Chapurlat, 1999, Le traitment médical de la dysplasie fibreuse des os, Rev Rhum, 66, 1 Pfeilschifter, 1998, Effect of Pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune-Albright syndrome, Med Klin, 93, 352, 10.1007/BF03044679 Lane, 1998, Fibrous dysplasia: effect of biphosphonate therapy on fracture rate, pain relief and NTX, Bone, 23, S463 González, 1999, Short-term therapy with oral olpadronate in active Paget's disease of bone, J Bone Miner Res, 14, 2042, 10.1359/jbmr.1999.14.12.2042 Weinstein, 1997, Long-term aminobisphosphonate treatment of fibrous dysplasia: spectacular increase in bone density, J Bone Miner Res, 12, 1314, 1315, 10.1359/jbmr.1997.12.8.1314 Lala, 2000, Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome, Acta Paediatr, 89, 188, 10.1111/j.1651-2227.2000.tb01214.x Zacharin, 2000, Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune-Albright syndrome, J Pediatr, 137, 403, 10.1067/mpd.2000.107836